首页> 外文期刊>Hepato-gastroenterology. >Undetected hepatocellular carcinoma in patients undergoing liver transplantation: is associated with favorable outcome.
【24h】

Undetected hepatocellular carcinoma in patients undergoing liver transplantation: is associated with favorable outcome.

机译:接受肝移植的患者未发现肝细胞癌:与良好的预后相关。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND/AIMS: The aim of the study was to define the clinical characteristics and outcome of patients found to have undetected hepatocellular carcinomas (HCC) at liver transplantation. Patients who underwent liver transplantation and were unexpectedly found to have a HCC despite prior workup showing normal alpha-fetoprotein levels and/or no visible radiological lesion were defined as having an undetected HCC. METHODOLOGY: Thirty-two of these patients had a histological diagnosis of HCC in the explanted liver. Undetected HCC was defined as a carcinoma found only on pathological evaluation of the explanted liver, with a pre-OLT workup showing a normal serum alpha-fetoprotein (AFP) level (<20 ng/mL) and/or no suspicious lesion on preoperative radiological evaluation. RESULTS: Nine patients had a tumor that met the criteria for an undetected HCC. The most common cause for transplantation was cryptogenic cirrhosis (44.4%). Tumor size was 2 cm or less in all patients, vascular invasion was detected in 11.1% of the patients, and tumor, node, metastasis (TNM) classification was stage I in 77.8%. Eight patients (88.9%) remained alive at the cessation of the analysis with a mean follow-up of 60 +/- 30.4 months. There was no tumor recurrence in any patient. Statistical analysis showed significant differences between undetected and detected HCCs when causes of pretransplantation liver disease, peak AFP level, tumor size, number of tumors, presence of vascular invasion or pathological differentiation were compared. Undetected HCCs were associated with a better survival rate after liver transplantation (p = 0.008). CONCLUSIONS: Patients with undetected HCCs at OLT have a favorable outcome with tumor-free survival. Most patients had small, early-stage HCCs, but the possibility of finding tumors greater than 2 cm, multifocal lesions, and vascular invasion exist despite thorough investigation. An exhaustive histopathological search of the explant for malignancy will allow for greater accuracy in prognosis.
机译:背景/目的:该研究的目的是确定在肝移植时发现未被发现的肝细胞癌(HCC)的患者的临床特征和结果。尽管先前的检查显示出正常的甲胎蛋白水平和/或无可见的放射病灶,但接受肝移植且出乎意料的发现患有HCC的患者被定义为未发现HCC。方法:其中32例患者的肝移植组织学诊断为HCC。未检测到的HCC被定义为仅在对移植肝脏的病理学评估中发现的癌,OLT前检查显示术前放射学检查显示血清甲胎蛋白(AFP)正常水平(<20 ng / mL)和/或无可疑病变评价。结果:9例患者的肿瘤符合未检出HCC的标准。移植的最常见原因是隐源性肝硬化(44.4%)。所有患者的肿瘤大小均在2 cm以下,在11.1%的患者中发现了血管浸润,在第一阶段的肿瘤,淋巴结转移(TNM)分类为77.8%。停止分析时,有8名患者(88.9%)仍然活着,平均随访60 +/- 30.4个月。所有患者均无肿瘤复发。统计分析显示,在比较移植前肝病的病因,AFP峰值水平,肿瘤大小,肿瘤数量,是否存在血管浸润或病理分化时,未发现和发现的HCC之间存在显着差异。未检测到的肝癌与肝移植后更好的生存率相关(p = 0.008)。结论:未检测到肝细胞癌的患者在无肿瘤生存方面具有良好的预后。大多数患者早期都有较小的肝癌,但尽管进行了深入研究,仍可能发现大于2 cm的肿瘤,多灶性病变和血管浸润。对恶性肿瘤进行详尽的组织病理学检查可提高预后的准确性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号